Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.69 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.69 |
| ▸ | JAK2 | O60674 | 5/20 | 0.69 |
| ▸ | MAP4K3 | Q8IVH8 | 5/20 | 0.69 |
| ▸ | JAK3 | P52333 | 3/20 | 0.69 |
| ▸ | PLK4 | O00444 | 2/20 | 0.69 |
| ▸ | AURKA | O14965 | 2/20 | 0.69 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.69 |
| ▸ | ABL1 | P00519 | 2/20 | 0.69 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.69 |
| ▸ | INSR | P06213 | 2/20 | 0.69 |
| ▸ | LCK | P06239 | 2/20 | 0.69 |
| ▸ | FES | P07332 | 2/20 | 0.69 |
| ▸ | CSF1R | P07333 | 2/20 | 0.69 |
| ▸ | LYN | P07948 | 2/20 | 0.69 |
| ▸ | RET | P07949 | 2/20 | 0.69 |
| ▸ | IGF1R | P08069 | 2/20 | 0.69 |
| ▸ | ROS1 | P08922 | 2/20 | 0.69 |
| ▸ | SRC | P12931 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19821490 | 0.93 | MET (0.71) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL3388109 | 0.93 | MET (0.71) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL18561630 | 0.92 | MET (0.70) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL18651455 | 0.92 | MET (0.66) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL20086735 | 0.92 | MET (0.66) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL22493294 | 0.92 | MET (0.66) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL18651460 | 0.92 | MET (0.66) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL22493281 | 0.92 | MET (0.66) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL1582503 | 0.92 | MET (0.75) | METALKJAK2MAP4K3JAK3 | |
| SCHEMBL1581764 | 0.92 | MET (0.75) | METALKJAK2MAP4K3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956302-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180064823-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180036416-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180028673-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028673-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | MET 2447/4885ALK 402/4885JAK2 2292/4885 |
| US-20180064823-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | MET 2447/4885ALK 402/4885JAK2 2292/4885 |
| US-20180036416-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | MET 2447/4885ALK 402/4885JAK2 2292/4885 |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | MET 2447/4885ALK 402/4885JAK2 2292/4885 |
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | MET 2447/4885ALK 402/4885JAK2 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.